Law360 (July 23, 2008, 12:00 AM EDT) -- As a litigator with regulatory experience, Dan Troy brings a unique vantage point to his newest role as general counsel and senior vice president at GlaxoSmithKline, where he is set to face a U.S. Department of Justice probe of the company's antidepressant Paxil and charges that the company delayed a generic release to keep profits high.
Troy, who is currently a partner in Sidley Austin LLP's life sciences practice, is set to join GSK on Sept. 2, the company announced Tuesday.
The pharmaceutical giant is embroiled...
GSK Snags Former FDA General Counsel Dan Troy
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
